Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Receivables: 2024-2025

Historic Change in Receivables for BridgeBio Pharma (BBIO) over the last 2 years, with Sep 2025 value amounting to $39.6 million.

  • BridgeBio Pharma's Change in Receivables rose 21885.71% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.0 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2024, which is 119.38% up from last year.
  • BridgeBio Pharma's Change in Receivables amounted to $39.6 million in Q3 2025, which was up 203.26% from -$38.4 million recorded in Q2 2025.
  • BridgeBio Pharma's Change in Receivables' 5-year high stood at $233.7 million during Q1 2024, with a 5-year trough of -$234.8 million in Q2 2024.
  • Over the past 2 years, BridgeBio Pharma's median Change in Receivables value was $4.2 million (recorded in 2024), while the average stood at $16.4 million.
  • Data for BridgeBio Pharma's Change in Receivables shows a peak YoY increase of 21,885.71% (in 2025) and a maximum YoY decrease of 52.71% (in 2025) over the last 5 years.
  • BridgeBio Pharma's Change in Receivables (Quarterly) stood at $4.2 million in 2024, then skyrocketed by 21,885.71% to $39.6 million in 2025.
  • Its Change in Receivables was $39.6 million in Q3 2025, compared to -$38.4 million in Q2 2025 and $110.5 million in Q1 2025.